Steven B.  Binder net worth and biography

Steven Binder Biography and Net Worth

CFO of MannKind
Steve brings more than 25 years of healthcare experience to MannKind, including leading financial operations at biopharmaceutical and medical technology companies. Since July 2017, he has guided MannKind’s financial strategy, setting us up for financial success so that we can help others truly thrive.

How he lives life more humann:
Steve can often be found golfing, mountain biking, hiking, Nordic skiing, and snowshoeing in and around the mountains of California.

What is Steven B. Binder's net worth?

The estimated net worth of Steven B. Binder is at least $3.88 million as of May 13th, 2024. Mr. Binder owns 845,967 shares of MannKind stock worth more than $3,882,989 as of May 20th. This net worth evaluation does not reflect any other investments that Mr. Binder may own. Additionally, Mr. Binder receives an annual salary of $854,280.00 as CFO at MannKind. Learn More about Steven B. Binder's net worth.

How old is Steven B. Binder?

Mr. Binder is currently 61 years old. There are 9 older executives and no younger executives at MannKind. The oldest executive at MannKind is Mr. John F. Bedard, Senior Vice President of Worldwide Regulatory Affairs, who is 74 years old. Learn More on Steven B. Binder's age.

What is Steven B. Binder's salary?

As the CFO of MannKind Co., Mr. Binder earns $854,280.00 per year. There are 3 executives that earn more than Mr. Binder. The highest earning executive at MannKind is Dr. Michael E. Castagna Pharm.D., CEO & Director, who commands a salary of $1,530,000.00 per year. Learn More on Steven B. Binder's salary.

How do I contact Steven B. Binder?

The corporate mailing address for Mr. Binder and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at (818) 661-5000 and via email at [email protected]. Learn More on Steven B. Binder's contact information.

Has Steven B. Binder been buying or selling shares of MannKind?

During the past quarter, Steven B. Binder has sold $15,593.58 in shares of MannKind stock. Most recently, Steven B. Binder sold 3,618 shares of the business's stock in a transaction on Monday, May 13th. The shares were sold at an average price of $4.31, for a transaction totalling $15,593.58. Following the completion of the sale, the executive vice president now directly owns 845,967 shares of the company's stock, valued at $3,646,117.77. Learn More on Steven B. Binder's trading history.

Who are MannKind's active insiders?

MannKind's insider roster includes Steven Binder (CFO), Michael Castagna (CEO), Alejandro Galindo (Insider), David Thomson (EVP), and Stuart Tross (Insider). Learn More on MannKind's active insiders.

Are insiders buying or selling shares of MannKind?

In the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 550,104 shares worth more than $2,472,279.96. The most recent insider tranaction occured on May, 13th when EVP Steven B Binder sold 3,618 shares worth more than $15,593.58. Insiders at MannKind own 3.0% of the company. Learn More about insider trades at MannKind.

Information on this page was last updated on 5/13/2024.

Steven B. Binder Insider Trading History at MannKind

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/13/2024Sell3,618$4.31$15,593.58845,967View SEC Filing Icon  
5/24/2023Sell47,810$4.67$223,272.70838,324View SEC Filing Icon  
7/31/2022Buy791$2.93$2,317.63728,997View SEC Filing Icon  
1/31/2022Buy711$3.17$2,253.87View SEC Filing Icon  
7/30/2021Buy748$2.99$2,236.52View SEC Filing Icon  
1/31/2021Buy1,557$1.33$2,070.81398,822View SEC Filing Icon  
7/31/2020Buy1,522$1.25$1,902.5033,265View SEC Filing Icon  
1/31/2020Buy2,168$0.95$2,059.6048,204View SEC Filing Icon  
7/31/2019Buy2,139$0.95$2,032.0546,036View SEC Filing Icon  
1/31/2019Buy1,860$1.07$1,990.203,620View SEC Filing Icon  
8/2/2018Buy1,760$1.31$2,305.601,760View SEC Filing Icon  
See Full Table

Steven B. Binder Buying and Selling Activity at MannKind

This chart shows Steven B Binder's buying and selling at MannKind by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MannKind Company Overview

MannKind logo
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Read More

Today's Range

Now: $4.59
Low: $4.51
High: $4.61

50 Day Range

MA: $4.41
Low: $4.05
High: $4.92

2 Week Range

Now: $4.59
Low: $3.17
High: $5.75


2,119,500 shs

Average Volume

2,800,918 shs

Market Capitalization

$1.25 billion

P/E Ratio


Dividend Yield